Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 18

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 18
---
 Notwithstanding
the foregoing, the number of shares potentially issuable upon exercise of the common warrants is limited by the number of available shares
of authorized Common Stock; accordingly, the aggregate number of shares of Common Stock potentially issuable in this offering is limited
to a total of 90,000,000 shares of Common Stock, with the number of shares of Common Stock potentially issuable upon exercise of the
common warrants determined by subtracting the aggregate number of shares of Common Stock or pre-funded warrants issued in this offering
from 90,000,000 shares. Each purchaser will receive a pro rata portion of such amount. As a result, the aggregate number of shares
of Common Stock underlying all of the common warrants may increase from 16,666,667 up to 73,333,333 (in each case, based
on an assumed public offering price of $0.48 per share), assuming full adjustment of the exercise price to the Floor Price and
giving effect to the “zero exercise price” provision.

When the above provisions in the common warrants are utilized, our stockholders will most likely suffer substantial dilution.

We will likely not receive any additional funds upon the exercise of the common warrants.

The common warrants may be exercised by way of a zero exercise price exercise, in which case the holder would not pay a cash purchase price upon exercise, but instead would receive upon such exercise the number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the common warrant multiplied by (ii) 3.0, subject to a limitation on the aggregate number of shares of Common Stock potentially issuable in this offering of 90,000,000 shares of Common Stock. The number of shares issuable on the exercise of the common warrants under the zero exercise price provision increases as the stock price declines. Accordingly, it is highly unlikely that a holder of the common warrants would wish to pay an exercise price in cash to receive one share of Common Stock when they could instead choose the zero exercise price option and pay no cash to receive three shares of Common Stock. As a result, we will likely not receive, and do not expect to receive, any additional funds upon the exercise of the common warrants.

The exercisability of the common warrants is contingent upon us obtaining Stockholder Approval. If we do not obtain such Stockholder Approval, the common warrants may never become exercisable.

The common warrants